ICD-10 A52.16 is officially defined as "Charcot's arthropathy (tabetic)." code A52.16 is referenced in 3 tracked payer policy changes from Independence Blue Cross, Aetna, and 1 other payer. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for code A52.16 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.
Independence Blue Cross MA05.010m updated HCPCS codes for ankle-foot orthoses effective 10/01/2026: code L1971 (customized prefabricated AFO) was revised, new code L1972 (off-the-shelf AFO) was added to medically necessary section, and ICD-10 codes for plantar fasciitis and plantar fascial fibromatosis were expanded with laterality specificity (M67.A01, M67.A02, M67.A09, M72.20, M72.21, M72.22), replacing the non-specific M72.2 code.
Aetna's clinical policy bulletin covers zoledronic acid for commercial medical plans. Zoledronic acid 5 mg (Reclast or generic) is considered medically necessary for postmenopausal osteoporosis, osteoporosis in men, glucocorticoid-induced osteoporosis, Paget's disease of bone, and treatment-related bone loss in men with prostate cancer receiving androgen deprivation therapy, when the listed criteria are met. Zoledronic acid 4 mg (formerly branded Zometa) is considered medically necessary for bone metastases from a solid tumor, certain breast cancer indications, hypercalcemia of malignancy, Langerhans cell histiocytosis with bone disease, multiple myeloma, and systemic mastocytosis with osteopenia or osteoporosis. Aetna considers all other indications experimental, investigational, or unproven.
Trigger point injection of abnormally sensitive areas in muscles, ligaments, joint capsules, tendons and related tissues may be considered medically necessary to relieve spasm and diminish myofascial pain. One reimbursement is made per site, per session, regardless of the number of trigger point injections, and separate billing for the injected drug is not allowed because it is included in the administration of the injection. Reimbursement is limited to ten sessions in a three-month period for tendon sheath, ligament, trigger point or ganglion cyst injections (CPT 20550), two injections per joint within thirty days for small and intermediate joints (CPT 20600 and 20605), and four services per site within thirty days for major joints or bursa (CPT 20610), and no coverage is allowed beyond these treatment limits.
Watch A52.16
Get one email when a payer policy names A52.16, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.
Get alerts for changes like this
Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.